Clinical Trials
12
3 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1832
Active, not recruiting
3
25.0%
Completed
5
41.7%
Recruiting
1
8.3%
Suspended
2
16.7%
Unknown
1
8.3%
No approval data available
- A comprehensive review of 43 studies published in The Lancet found no evidence that paracetamol use during pregnancy increases the risk of autism spectrum disorder, ADHD, or intellectual disability in children. - The analysis, which included more than a million births and prioritized sibling-comparison studies to control for genetics and environmental factors, contradicts previous claims linking the medication to neurodevelopmental disorders. - Medical authorities including the MHRA reaffirmed that paracetamol remains the safest first-line treatment for pain and fever during pregnancy when taken as directed. - Researchers warn that discouraging appropriate paracetamol use could cause greater harm than the drug itself, particularly as untreated maternal fever has been linked to miscarriage and birth complications.
- Durham University spin-out Magnitude Biosciences raised £700,000 through investors and grants to develop its WormGazer high-throughput screening platform for age-related conditions and difficult-to-treat diseases. - The company's technology integrates robotics, machine learning, and liquid culture systems to screen thousands of compounds weekly, with several top 10 pharmaceutical companies already using the platform in pilot programs. - The funding will enable creation of highly skilled jobs in robotics, software engineering, and biological sciences at the company's NETPark facility in County Durham. - Investment was led by Maven and included NPIF II - Maven Equity Finance, Finance Durham Fund, existing investor Northstar Ventures, and matched grant funding from Innovate UK.
